Press Releases Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
6.85 ^USD	-0.87%		-10.69%	-30.81%

May. 28	HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating	MT
May. 24	Guggenheim Adjusts Tango Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	May. 23	PR
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	May. 23	AQ
Tango Therapeutics : Corporate Presentation	May. 23	PU
Tango Therapeutics Announces Discontinuation of TNG348 Program	May. 23	BU
Tango Therapeutics : Corporate Presentation	May. 08	PU
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights	May. 08	BU
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 01	BU
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	Mar. 18	BU
Tango Therapeutics to Participate in Upcoming Investor Conferences	Mar. 06	BU
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	Mar. 05	AQ
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	Jan. 31	AQ
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 05	AQ
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	Jan. 04	PR
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	Jan. 04	AQ
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	Jan. 03	AQ
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	Nov. 13	AQ
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights	Nov. 08	AQ
Tango Therapeutics to Present at the Jefferies London Healthcare Conference	Nov. 07	AQ
MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023	23-10-27	AQ
Thinking about buying stock in Nikola Corp, Eos Energy Enterprises, Applied Therapeutics, Tango Therapeutics, or Cabaletta Bio?	23-09-25	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Press Releases

Filters